ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

SIMPONI ARIA® Ankylosing Spondylitis: ASAS Response Rates

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies

Treating to Target(s) With Interleukin-17 Inhibitors - Charles W. Lynde, Jennifer Beecker, Jan Dutz, Cathy Flanagan, Lyn C. Guenther, Wayne Gulliver, Kim Papp, Proton Rahman, Dalton Sholter, Gordon E. Searles, 2019

The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology

The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort Study

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. - Abstract - Europe PMC

UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts

PDF) Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration

Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program

Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?, Arthritis Research & Therapy